

ARM Research

research@armsecurities.com.ng +234 1 270 1652

27 October 2014

Initial View

9 months ended 30th September, 2014

Recommendation: STRONG BUY

United Bank for Africa Plc. (UBA) reported 12% YoY growth (6M 14: +10%YoY) in gross earnings to №205.8 billion for the 9 months to September 2014. PBT was 2% lower YoY (6M 14: -13%YoY) at №42.5 billion while PAT declined 10% YoY to №33.6 billion (6M 14: +20%YoY).

Revenues moderate from high base

Q3 14 gross earnings was flat (+1%) QoQ at ¥69.4 billion, 2% above our estimates. Interest income improved, rising 5% QoQ to ¥50.9 billion but was not as strong as we expected, falling 7% short of our estimates. Much of the gains was from volume growth as earnings assets expanded 7% on aggregate driven by loans (+10% to ¥1 trillion) and securities (+6% to ¥731 billion). Nonetheless, the accretion was tempered by a 50bps QoQ dip in asset yields. On the flip side, non-interest revenue (NIR) declined but not as much as we expected, falling 7% QoQ to ¥19.4 billion, 18% ahead of our estimates. The outperformance suggests to us that CBN's restoration of charges on ATM withdrawals helped cushion expected industry-wide pressures on NIR. Regardless, fee income contracted 14% QoQ to ¥12 billion with trading gains (+25% QoQ) providing some offset.

| | 20 |)14 – 9M'm | 2013 – 9M'm | %chg |
|--|------------------------------------|--------------------------|--|--|
| Davienija | | 20E 929 | 10 <i>1</i> /EO | 12% |
| Revenue PBT | | 205,838 42,543 | 184,459 43,428 | -2% |
| гы Гах | | (8,915) | (6,057) | -2% 47% |
| rax PAT | | 33,628 | 37,371 | -10% |
| Balance She | et Data | 33,020 | 37,371 | -10/ |
| | | 14-Sept 'm | 2013 -Dec 'm | %chc |
| Cash | | 747,090 | 717,587 | 4% |
| _oans | | 991,189 | 937,620 | 6% |
| Deposit | | 2,093,385 | 2,161,182 | -3% |
| ixed Asset | | 82,470 | 75,409 | 9% |
| Vet Assets | | 246,151 | 235,036 | 5% |
| Stock Data Price | | | | N 5.66 |
| 52 week rar Market Cap 1-month Av | . (N'm) | | | ,323.72 294,57 <i>6</i> |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick | . (N'm) g. Vol Ticker ker | rice Tre | 188 14,2 U | 323.72 294,576 4> JBA: NL JBA.LG |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick | . (N'm) g. Vol Ticker ker | rice Tre | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- | . (N'm) g. Vol Ticker ker | rice Tre | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap I-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- | . (N'm) g. Vol Ticker ker | rice Tre | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap I-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 | . (N'm) g. Vol Ticker ker | JA~~~ | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap I-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 | . (N'm) g. Vol Ticker ker | JA~~~ | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 | . (N'm) g. Vol Ticker ker | Apr-14 - Apr-14 - Apr-14 | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 | . (N'm) g. Vol Ticker ker | JA~~~ | 188 14,2 U | ,323.72 294,576 4> JBA: NL |
| Market Cap I-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 | . (N'm) g. Vol Ticker ker Share P | JA~~~ | Jun-14 - Aug-14 - Aug | 7,323.72 4,9 JBA: NL JBA.LG |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 5 ET-to | . (N'm) g. Vol Ticker ser Share P | Apr-14 - | 188 14,2 U | 7,323.72 294,57¢ 4x JBA: NL JBA.LG |
| Market Cap 1-month Av Curr. PE Bloomberg Reuters Tick UBA PIc- 11 9 7 5 ET-to | . (N'm) g. Vol Ticker ser Share P | Apr-14 - | Adeolu O | 7,323.72 294,57¢ 4x JBA: NL JBA.LG |

But costs expand more markedly, dampening profits

- Matching asset growth, deposit-driven 7% expansion in funding base pushed interest expense 6% higher QoQ to ¥24.1 billion, 13% ahead of our estimates. Buttressing the wholly volume driven nature of the rise, annualized WACF shaved off 10bps to 3.9%.
- In addition, operating expenses rose 8% QoQ to ¥32.2 billion, in line with our estimates. Whilst personnel expenses fell 18% QoQ to ¥12.2 billion, other opex jumped 38% to ¥18.6 billion with rise in the latter reflecting both investments in platform as well as greater regulatory costs. Annualised CIR came in at 67.5%, 50bps ahead of FY14 estimate.
- On a positive note, after tripling QoQ in Q2 14, impairment charges collapsed 8% QoQ in Q3 14 to ~N300 million, 90% behind our estimates. This helped offset some of the cost growth but was too small to avert damage to bottom-line. Cost of risk improved 10bps from 6M 14 to 0.3% and remains well short of our 1% FY14 estimate.
- Largely reflecting higher interest expense and opex, Q3 14 PBT declined 11% QoQ to \$\frac{\text{\tex

Significant price pressures lead to rating upgrade

• The resumption of balance sheet expansion for UBA reinvigorates the potential for asset creation to meet expectations. Considering key line items are in line with projections, our revisions, and consequent changes to FVE, are likely to be mild. However, UBA has been one of the names most affected by recent market weakness and the significant cutback in prices make valuation discounts more compelling: current PE and P/Bv of 4x and 0.7x compare favourably with respective peer averages of 6x and 1x respectively. Based strictly on the upside opened up by the price contraction, our rating (FVE: N9.3) on UBA is likely to climb two notches to STRONG BUY.

Summary of forecasts

| Quarterly Forecasts | Q4 2014E | Q1 2015E | Q2 2015E | Q3 2015E | |
|-------------------------|-----------|-----------|-----------|-----------|-----------|
| Net interest income | 31,933 | 30,871 | 31,008 | 31,615 | |
| Non-interest income | 18,794 | 18,921 | 18,997 | 19,377 | |
| Total Revenue | 50,727 | 49,792 | 50,084 | 50,992 | |
| Total Operating Costs | (33,248) | (32,720) | (32,851) | (33,508) | |
| Operating Profit | 17,479 | 17,072 | 17,233 | 17,483 | |
| Impairment Charge | (4,187) | (6,079) | (6,104) | (6,226) | |
| Pre-tax Profit | 13,292 | 10,992 | 11,129 | 11,257 | |
| Tax | (3,377) | (841) | (844) | (861) | |
| Post-tax Profit | 9,954 | 10,151 | 10,192 | 10,396 | |
| | | | | | |
| Income Statement ('000) | 2013A | 3Q 2014A | 2014E | 2015E | 2016E |
| Net interest income | 103,231 | 81,960 | 113,893 | 123,981 | 135,263 |
| Non-interest income | 73,762 | 56,429 | 75,223 | 75,986 | 80,982 |
| Total Revenue | 176,993 | 138,389 | 189,116 | 199,967 | 216,246 |
| Total Operating Costs | 107,851 | 93,460 | 126,708 | 131,405 | 139,374 |
| Operating Profit | 69,142 | 44,929 | 62,408 | 68,562 | 76,872 |
| Impairment Charge | 13,078 | 2,347 | 6,534 | 24,416 | 25,687 |
| Pre-tax Profit | 56,058 | 42,543 | 55,874 | 44,146 | 51,185 |
| Tax | 9,457 | 8,915 | 12,292 | 8,829 | 11,261 |
| Post-tax Profit | 46,601 | 33,628 | 43,582 | 35,317 | 39,924 |
| Balance Sheet ('000) | | | | | |
| Assets | 2013A | 3Q 2014A | 2014E | 2015E | 2016E |
| Cash & Short term funds | 717,587 | 747,090 | 765,511 | 745,765 | 742,095 |
| Due from banks | 26,251 | 18,232 | 28,099 | 41,018 | 45,213 |
| Net Loans | 937,620 | 991,189 | 1,060,927 | 1,315,407 | 1,465,805 |
| Fixed Assets | 75,409 | 82,470 | 70,248 | 102,546 | 113,032 |
| Other Assets | 885,429 | 812,660 | 885,120 | 1,213,460 | 1,401,601 |
| Total Assets | 2,642,296 | 2,651,641 | 2,809,904 | 3,418,196 | 3,767,746 |
| Liabilities | | | | | |
| Deposits | 2,161,182 | 2,093,385 | 2,306,363 | 2,798,738 | 3,053,761 |
| Due to banks | 60,582 | 82,095 | 64,785 | 79,510 | 70,201 |
| Borrowings | 104,519 | 159,533 | 142,528 | 159,019 | 196,564 |
| Other liabilities | 80,977 | 70,477 | 77,743 | 143,117 | 189,544 |
| Total liabilities | 2,407,260 | 2,405,490 | 2,591,419 | 3,180,384 | 3,510,070 |
| Shareholders' fund | 235,036 | 246,151 | 218,485 | 237,812 | 257,677 |
| Key ratios | | | | | |
| EPS | 1.55 | 1.12 | 1.42 | 1.15 | 1.30 |
| ROE | 20% | 5% | 20% | 15% | 15% |
| ROA | 1.8% | 0.5% | 1.3% | 1.1% | 1.1% |
| Loan to Asset | 35% | 39% | 38% | 39% | 39% |
| Cost to income | 61% | 69% | 68% | 66% | 65% |
| Net Profit Margin | 21% | 17% | 14% | 13% | 13% |
| Capital adequacy ratio | 23% | 22% | 17% | 16% | 15% |
| Liquidity ratio | 33% | 35% | 33% | 27% | 25% |

Source: Company financials, ARM Estimates

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6 month period (minimum) to the review date. We adopt a 5 point rating system for this category of stocks and a 3 point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

| TOP 20 | | NON-TOP 20 | |
|-------------|------------|------------|-----------|
| Rating | Deviation | Rating | Deviation |
| STRONG BUY | >20% | BUY | >20% |
| OVERWEIGHT | 10% — 20 % | NEUTRAL | 5% — 20 % |
| NEUTRAL | 0% — 10 % | SELL | <5% |
| UNDERWEIGHT | -5% — 0% | | |
| SELL | <-5% | | |

| RECOMMENDATION KE | EY |
|-------------------|--|
| Rating | Recommendation |
| BUY | Accumulate security to a substantial extent constrained only by portfolio diversification considerations |
| OVERWEIGHT | Accumulate security to an extent moderated by cognizance of its benchmark weight |
| | Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise— |
| NEUTRAL | subject to reasonable portfolio constraints |
| UNDERWEIGHT | Minimise exposure to security taking cognizance of its index weighting |
| SELL | Sell-off security completely from portfolio |

All rights reserved. Unauthorised use, reproduction, distribution or disclosure of this document is strictly prohibited.

This material has been issued by Asset & Resource Management Company Limited ("ARM"), a Company regulated by the Nigerian Securities and Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARM and its analysts believe to be reliable. Neither ARM nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARM, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARM. By accepting this document, you agree to be bound by the foregoing limitations.